Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thirty-four healthy human subjects were exposed to shallow air saturation for 48 h [1.77 ATA (25.5 fsw) n = 19, 1.89 ATA (29.5 fsw) n = 15] and then decompressed to 1 ATA (0 fsw) in about 2 min. Symptoms included fatigue, limb and joint pain, headache, myalgias, and pruritus. No subject of 19 was diagnosed as having decompression sickness (DCS) after the shallower exposure, but 4 of 15 were diagnosed and treated for DCS subsequent to the deeper exposure. Almost all subjects in both groups had Doppler-detectable venous gas emboli (VGE) lasting up to 12 h postdecompression. Treated subjects had a recurrence of VGE several hours after the hyperbaric oxygen treatment. Only the duration of VGE, and not the VGE score, correlated with symptoms; and only the subjects body weight and age correlated with the VGE variables. This study indicates that hyperbaric air exposures of this magnitude are not as benign as previously thought.
 ...
PMID:Direct ascent from shallow air saturation exposures. 353

Almitrine bismesylate is a pharmacologically unique respiratory stimulant. It enhances respiration after both acute and chronic administration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. In comparison with traditional central-acting respiratory stimulants, almitrine has advantages of oral activity, prolonged duration of effect, and an improved adverse effect profile. Almitrine is generally well tolerated, with headache and minor gastrointestinal disturbances being the most frequently observed side effects. This investigational agent has been shown to increase arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease both at rest and during exercise through increased ventilation and improved ventilation/perfusion matching. It may also prove useful in the treatment of nocturnal oxygen desaturation because of its ability to reduce the frequency and severity of nocturnal hypoxemia without impairing the quality of sleep. Additional research is needed to further define the role of almitrine in the relief of hypoxemia.
 ...
PMID:Almitrine bismesylate. 355 28

An acute febrile illness associated with unloading silos occurs more frequently than any other farm associated respiratory illness in mid state New York. This report describes 29 cases of organic dust toxic syndrome (also known as pulmonary mycotoxicosis) occurring in 24 men and one woman with a mean age of 29 years. In 16 instances more than one worker was exposed to the dust, and in 12 of these shared exposures more than one worker became ill. Patients presented 5.3 (SD 3.3) hours after inhalation of organic dust and mould with fever (79%), myalgia (76%), chest tightness (72%), cough (66%), and headache (59%). The mean temperature was 38.7 degrees C and the mean white blood cell count 13.2 X 10(9)/l. In contrast to patients with allergic alveolitis, nearly all these patients had normal breath sounds, chest radiographs, and arterial oxygen saturation. Tests for precipitating antibodies to farmer's lung disease antigens gave negative results in all 26 episodes in which they were done; of these, 10 had no evidence of precipitating antibodies to an aqueous extract of the silage associated with their own illness. Organic dust toxic syndrome appears to be a common and substantial respiratory hazard to young farm workers. Despite being frequently mis-diagnosed as farmer's lung, organic dust toxic syndrome is clearly a distinctly different disease process.
 ...
PMID:Organic dust toxicity (pulmonary mycotoxicosis) associated with silo unloading. 359 53

Animal studies suggest that pulmonary oxygen toxicity proceeds more slowly in diluted oxygen breathing mixtures than in pure oxygen at the same inspired partial pressure. We exposed 12 healthy subjects to air at 5 ATA (PiO2 = 1.05 ATA) in a hyperbaric chamber for 48 h, and compared the rate of development of symptoms of O2 toxicity to rates seen in previous studies using 100% O2 at 1 ATA. Symptoms consisted of chest tightness, cough, substernal discomfort, exertional dyspnea, anorexia, nausea and vomiting, headache and digital paresthesias starting at about 12 h, and continuing several days into the recovery period. Pulmonary function changes consisted of significant decrements in vital capacity, flow rates, and DLCO. Initial recovery was in a 0.50 ATA oxygen atmosphere, with the majority of subjects showing definite recovery in both symptoms and pulmonary function. Subjects showed complete recovery in about 8 d, although symptoms of fatigue and exertional dyspnea continued for a month in some cases. In contrast, none of the above changes were noted in an additional 6 subjects exposed to a 5 ATA environment with 6% oxygen (PiO2 = 0.30 ATA). No change in resting gas exchange, as indicated by alveolar-arterial oxygen gradients, was detected in either group. Comparison of these data to that for pure oxygen studies reveals no significant difference in the progression or character of pulmonary oxygen toxicity.
 ...
PMID:Progression of and recovery from pulmonary oxygen toxicity in humans exposed to 5 ATA air. 361 41

Ten patients suffering from cluster headache or variants of cluster headache were made to inhale oxygen in an attempt to check these attacks. This treatment proved a success with six patients with classic ("episodic") cluster headache, as well as with another patient suffering from secondary chronic cluster headache. One patient with primary chronic cluster headache and another with chronic paroxysmal hemicrania (PCH) experienced only temporary relief and a female patient with PHC showed no reaction to oxygen inhalation. The patient who suffered from secondary chronic cluster headache has had no further attacks in the four years following this treatment.
 ...
PMID:[Cluster headache and chronic paroxysmal hemicrania--effectiveness of oxygen inhalation]. 372 24

Nocturnal attacks are symptomatic of numerous primary headache syndromes. It has proven possible to verify, with polygraphic sleep recordings, a strict correlation between the onset of headache attacks and the rapid eye movements (REM) stage for migraineurs, patients with chronic paroxysmal hemicrania and cluster headache (CH). The purpose of this study was to investigate the correlation between attack onset of chronic CH and sleep stages, the REM stage in particular. Nine patients from our headache outpatient service with a diagnosis of CH were examined in this study. All medication was discontinued at least one week prior to sleep polygraphias, which were conducted in a sleep laboratory on two consecutive nights. Any attacks were treated with oxygen inhalation during the drug-free period. EEG, EMG, and EOG were continuously monitored during the sleep polygraphias. Eight patients had 25 CH attacks during 12 of the 17 nights recorded. Only three of these patients had arousals with attacks in the REM stage and these amounted to five of the 25 recorded attacks. Eleven attacks were in stage 2, four in stage 1 and two in stage 3. These results correlate with recent findings according to which headache attacks were often related to REM in episodic CH, but rarely in the chronic type. Whether or not different pathogenic mechanisms are involved in the episodic and the chronic type of CH is a matter for further discussion.
 ...
PMID:Onset of nocturnal attacks of chronic cluster headache in relation to sleep stages. 372 16

59 patients with cluster headache are discussed. Treatment can be divided into treatment of the acute attack, and prophylactic treatment. The acute attack can be interrupted in most cases by ergotamine, either sublingually or in the form of suppositories. A number of patients respond to the inhalation of pure oxygen. Most patients with the episodic type of cluster headache do well on prophylactic treatment with methysergide. If they prove refractory to this drug, treatment with lithium salts can be instituted. Most patients with the chronic type of cluster headache respond favourably to lithium therapy.
 ...
PMID:[Cluster headache]. 374 13

We report a series of 28 pediatric carbon monoxide exposures. Sixteen patients (57%) were judged to have potentially toxic carboxyhemeglobin (COHb) levels (greater than 15%). In this group the range of COHb blood levels was 16.7% to 44.0% (mean = 26.5%). An unusually high incidence of syncope (56.3%, 9/16) and lethargy (68.7%, 11/16) was observed. Every patient with a COHb level greater than or equal to 24% experienced syncope; a marked departure from published adult values. Lethargy was reported at a mean COHb concentration of 25.9%. All patients with levels over 25% COHb, neurologic findings, acidosis, or syncope were considered candidates for hyperbaric oxygen therapy (HBOT). No morbidity from HBOT was encountered. Eighty-nine percent (25/28) of the patients are reportedly doing well, with no late sequelae identified. Delayed neurologic sequelae in three patients include chronic headaches, memory difficulties, or decline in school performance.
 ...
PMID:Pediatric carbon monoxide toxicity. 383 44

Nineteen men, aged 20 to 50 years, were treated in a double-blind crossover study comparing oxygen v air inhalation at 6 L/min via nonrebreathing face masks for 15 minutes or less, for up to six headaches. Patients scored their own degree of relief for each treatment as none, slight, substantial, or complete relief. The average (+/- SE) relief score for all oxygen-treated patients was 1.93 +/- 0.22 out of a possible total score of 3.0, and for air the treatment relief score was 0.77 +/- 0.23. This difference is highly statistically significant by an analysis-of-variance F test; it documents that patients with cluster headache can benefit from oxygen inhalation during acute attacks.
 ...
PMID:Treatment of cluster headache. A double-blind comparison of oxygen v air inhalation. 388 21

Diltiazem is an orally and intravenously active calcium channel blocking agent shown to be an effective and well-tolerated treatment for stable angina and angina due to coronary artery spasm. Its efficacy in these diseases has generally been similar to that of nifedipine or verapamil - alternative calcium channel blockers with which diltiazem has many electrophysiological, haemodynamic, and antiarrhythmic similarities. The antianginal mechanism of diltiazem cannot be precisely described; however, it appears to increase myocardial oxygen supply and decrease myocardial oxygen demand, mainly by coronary artery dilatation and/or via both direct and indirect haemodynamic alterations. Diltiazem has also shown substantial efficacy in the treatment of unstable angina, hypertension, and supraventricular tachyarrhythmias, but further study is necessary before its place in the treatment of these diseases may be clearly established. Although headache due to peripheral vasodilatation and depression of atrioventricular nodal conduction may be troublesome, side effects occur in only 2 to 10% of patients receiving diltiazem and are generally minor in nature. Thus, diltiazem offers a worthwhile alternative to other agents currently available for the treatment of angina pectoris. Although the infrequency of serious side effects may offer an advantage, its relative place in therapy compared with that of other calcium channel blockers remains to be clarified.
 ...
PMID:Diltiazem. A review of its pharmacological properties and therapeutic efficacy. 389 2


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>